Susan Altschuller | VP, IR |
Ludwig Hantson | CEO & Director |
Paul Clancy | EVP & CFO |
John Orloff | EVP and Head, Research & Development |
Brian Goff | EVP & Chief Commercial Officer |
Geoffrey Porges | Leerink |
Terence Flynn | Goldman Sachs Group |
Kennen MacKay | RBC Capital Markets |
Geoffrey Meacham | Barclays Bank |
Christopher Raymond | Piper Jaffray Companies |
Paul Matteis | Stifel, Nicolaus & Company |
Robyn Karnauskas | Citigroup |
Ying Huang | Bank of America Merrill Lynch |
Anupam Rama | JPMorgan Chase & Co. |
Matthew Harrison | Morgan Stanley |
Philip Nadeau | Cowen and Company |
Martin Auster | Crédit Suisse |
Joshua Schimmer | Evercore ISI |
Good morning, welcome to the Alexion Pharmaceuticals Inc. Fourth Quarter and Full Year 2018 Results Conference Call. Today's call is being recorded.
For opening remarks and introductions, I would now like to turn the call over to Susan Altschuller, Vice President Investor Relations. Go ahead, ma'am.